Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Alternative Names: Amorfix EP-AD; Disease specific epitope (DSE) monoclonal antibodies; Neurodegenerative disorders monoclonal antibodies - Amorfix Life Sciences; Neurodegenerative disorders vaccines - Amorfix Life Sciences

Latest Information Update: 28 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences; University of British Columbia
  • Class Diagnostic agents; Vaccines
  • Mechanism of Action Immunomodulators; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Research Amyotrophic lateral sclerosis
  • Suspended Creutzfeldt-Jakob disease
  • No development reported Alzheimer's disease

Most Recent Events

  • 28 Apr 2019 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in Canada (Parenteral, Injection)
  • 28 Mar 2017 Preclinical development in Amyotrophic lateral sclerosis and Alzheimer's disease is ongoing in Canada
  • 08 Oct 2015 ProMIS Neurosciences expands exclusive license agreement with the University of British Columbia to gain worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications and enhancements to ProMIS™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top